trial · primary record
MIL62
Systemic Lupus Erythematosus
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 123 |
| Primary completion | 2026-07-02 |
| Primary endpoint | Part A and Part B:Percentage of participants achieving SRI-4 at Week 12 |
| Registry ID | NCT05796206 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:05.469Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05796206
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.